The firm’s 50-day moving average price is $17.07 and its 200-day moving average price is $18.99. Zacks Investment Research downgraded Editas Medicine from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. As of quarter end Tiaa Cref Investment Management LLC had bought a total of 131,389 shares growing its holdings by 715.7%.

In the last earnings report the EPS was $-3.09 and is estimated to be $-3.04 for the current year with 40,729,000 shares presently outstanding. J P Morgan Chase & Co set a $27.00 price target on Editas Medicine and gave the stock a “hold” rating in a report on Wednesday. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company.

Editas Medicine, Inc. has a 12-month low of $12.43 and a 12-month high of $29.20. Cann assumed coverage on shares of Editas Medicine in a report on Monday, July 17th. (NASDAQ:EDIT)’s 14-day Relative Strength Index (RSI) has reached 65.36, putting it inside a neutral zone. Its revenue totaled $1.4 million up 55.56% from the previous quarter.

Editas Medicine received a price-target increase Thursday from Chardan Capital Markets after the genome-editing company announced late Wednesday the achievement of a second milestone under its collaboration with Juno Therapeutics (JUNO) amid technical progress toward overcoming the tumor microenvironment in a research program. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, July 12th.

Editas Medicine, a genome editing company. (NASDAQ:EDIT). Gerald Frank Cox, Chief Medical Officer acquired $56,600 worth of shares at an average price of $14.15 on Friday the 2nd. The company now has a consensus rating of “Buy” and an average target price of $26.03. Dealing with market volatility is normal, but exploring all aspects of a company may be a good way to combat day to day volatility. State Street has an ownership of 105,167 stocks of the firms shares valued $1,708,000 after scooping up an extra 2,476 shares through out the quarter.

Editas Medicine (EDIT) transacted up 11.31% throughout intraday market trading on Early Thur, topping $21.95. the share had a trading volume of 1,767,126 Stocks.

Editas Medicine (NASDAQ EDIT) opened at 17.14 on Friday. UBS Group AG now owns 78,217 shares of the company’s stock worth $1,746,000 after buying an additional 68,990 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Editas Medicine during the first quarter worth approximately $269,000. The stock is expected to report revenue as high as $4.4 Million and as low as $0.5 Million per share. Analysts expect next quarter’s EPS to be $-0.78 and the next full year EPS is projected to be $-3.20. Fox Run Management L.L.C. purchased a new position in Editas Medicine during the first quarter worth $272,000.

Equity analyst Oppenheimer added EDIT to its research portfolio with a rating of “Perform”. Editas Medicine reported sales of $3.39 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15%. Boris Nikolic, Director disclosed the purchase of 35,000 shares of EDIT stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem.

A number of analysts have issued reports on EDIT shares. If you are accessing this report on another publication, it was illegally copied and republished in violation of worldwide trademark & copyright laws. The legal version of this piece can be accessed at Proshare Advisors LLC owns 24,211 shares valued at $406,000.

Consequently Editas Medicine Cmn (NASDAQ:EDIT)’s weekly and monthly volatility is 8.14%, 6.74% respectively. The shares were purchased at an average price of $14.07.

Director Kevin Bitterman sold 1,000,000 shares at an average price of $17.00 on Monday the 22nd.

Recent Trading for Editas Medicine, Inc. The information was declared in a document with the Security and Exchange Commission, which is available at this link. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment.